The effect of rivaroxaban on myocardial infarction in the ATLAS ACS 2 - TIMI 51 trial

European heart journal. Acute cardiovascular care

Volumn 4, Issue 5, 2015, Pages 468-474

  Cavender, Matthew A ^a   Gibson, C Michael ^a   Braunwald, Eugene ^a   Wiviott, Stephen D ^a   Murphy, Sabina A ^a   Toda Kato, Eri ^a   Plotnikov, Alexei N ^b   Amuchástegui, Marcos ^c   Oude Ophuis, Ton ^d   van Hessen, Maarten ^e   Mega, Jessica L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c HOSPITAL PRIVADO   (Argentina)

^d CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^e GROENE HART HOSPITAL   (Netherlands)

Author keywords

acute coronary syndrome; Anti thrombotic therapy; secondary prevention

Indexed keywords

BIOLOGICAL MARKER; BLOOD CLOTTING FACTOR 10A INHIBITOR; CREATINE KINASE MB; RIVAROXABAN; TROPONIN;

ACUTE CORONARY SYNDROME; CONTROLLED STUDY; DRUG ADMINISTRATION; FIBRINOLYTIC THERAPY; HUMAN; METABOLISM; MIDDLE AGED; MYOCARDIAL INFARCTION; PATHOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL; SECONDARY PREVENTION; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; BIOMARKERS; CREATINE KINASE, MB FORM; DRUG ADMINISTRATION SCHEDULE; FACTOR XA INHIBITORS; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; RIVAROXABAN; SECONDARY PREVENTION; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; TROPONIN;

EID: 84975217579     PISSN: None     EISSN: 20488734     Source Type: Journal    
DOI: 10.1177/2048872614554109     Document Type: Article

References (0)